Ocumension Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Ocumension Therapeutics' es Victor Liu , nombrado en Aug 2018, tiene una permanencia de 5.67 años. compensación anual total es CN¥5.11M, compuesta por 51.8% salario y 48.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.38% de las acciones de la empresa, por valor de HK$177.45M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 4 años, respectivamente.

Información clave

Victor Liu

Chief Executive Officer (CEO)

CN¥5.1m

Compensación total

Porcentaje del salario del CEO	51.8%
Permanencia del CEO	5.8yrs
Participación del CEO	4.4%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Victor Liu en comparación con los beneficios de Ocumension Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CN¥380m
Sep 30 2023	n/a	n/a	-CN¥399m
Jun 30 2023	n/a	n/a	-CN¥418m
Mar 31 2023	n/a	n/a	-CN¥411m
Dec 31 2022	CN¥5m	CN¥3m	-CN¥403m
Sep 30 2022	n/a	n/a	-CN¥393m
Jun 30 2022	n/a	n/a	-CN¥383m
Mar 31 2022	n/a	n/a	-CN¥322m
Dec 31 2021	CN¥5m	CN¥4m	-CN¥260m

Compensación vs. Mercado: La compensación total de Victor($USD704.94K) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD394.47K).

Compensación vs. Ingresos: La compensación de Victor ha aumentado mientras la empresa no es rentable.

CEO

Victor Liu (51 yo)

5.8yrs

Permanencia

CN¥5,106,000

Compensación

Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ye Liu	CEO & Executive Director	5.8yrs	CN¥5.11m	4.38% CN¥ 217.2m
Zhaopeng Hu	Chief Development Officer & Executive Director	3.9yrs	CN¥2.15m	0.54% CN¥ 26.6m
Tim Ruan	CFO & Joint Company Secretary	1.3yrs	sin datos	sin datos
DongHong Chen	Chief Medical Officer	4.6yrs	sin datos	sin datos
Qinglei Zuo	Chief Commercial Officer	3.3yrs	sin datos	sin datos
Tingchan Chen	Joint Company Secretary	less than a year	sin datos	sin datos

3.6yrs

Permanencia media

44yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1477 se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ye Liu	CEO & Executive Director	5.5yrs	CN¥5.11m	4.38% CN¥ 217.2m
Zhaopeng Hu	Chief Development Officer & Executive Director	4.1yrs	CN¥2.15m	0.54% CN¥ 26.6m
Yanling Cao	Non-Executive Director	4.9yrs	sin datos	sin datos
Ting Yuk Wu	Independent Non-Executive Director	3.9yrs	CN¥647.00k	sin datos
Lian Yong Chen	Non-Executive Chairman of the Board	6yrs	sin datos	12.74% CN¥ 631.6m
Yumeng Wang	Non-Executive Director	3.2yrs	sin datos	sin datos
Zhenyu Zhang	Independent Non-Executive Director	2.1yrs	CN¥121.00k	sin datos
Yiran Huang	Independent Non-Executive Director	3.9yrs	CN¥162.00k	sin datos
Wei Li	Non-Executive Director	6.1yrs	sin datos	sin datos

4.1yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de 1477 se considera experimentada (4 años de antigüedad promedio).

Ocumension Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Board Member recently sold HK$246k worth of stock

Ocumension Therapeutics Announces Executive Changes

Less than half of directors are independent

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

Consensus forecasts updated

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 in the United Kingdom

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-101

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiatinga Phase III Clinical Trial of OT-101 Accepted in United Kingdom

Ocumension Therapeutics Announces Investigational New Drug Application for Initiating A Multi-Regional Phase Iii Clinical Trial in the People's Republic of China for OT-101

Non-Executive Director has left the company

Ocumension Therapeutics Announces Board Changes

Ocumension Therapeutics, Annual General Meeting, Jun 29, 2021

New 90-day low: HK$22.50

Ocumension Therapeutics to Report Fiscal Year 2020 Results on Mar 19, 2021

Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial

Ocumension Therapeutics Announces Second Phase III Clinical Trial of OT-301 Approved in China